227 related articles for article (PubMed ID: 16100339)
21. Scleroderma lung disease: evolving understanding in light of newer studies.
Antoniou KM; Wells AU
Curr Opin Rheumatol; 2008 Nov; 20(6):686-91. PubMed ID: 18946329
[TBL] [Abstract][Full Text] [Related]
22. Bronchoalveolar lavage in systemic sclerosis with lung involvement: role and correlations with functional, radiological and scintigraphic parameters.
Volpinari S; La Corte R; Bighi S; Ravenna F; Prandini N; Lo Monaco A; Trotta F
Rheumatol Int; 2011 Sep; 31(9):1183-8. PubMed ID: 20352228
[TBL] [Abstract][Full Text] [Related]
23. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis.
Giacomelli R; Valentini G; Salsano F; Cipriani P; Sambo P; Conforti ML; Fulminis A; De Luca A; Farina G; Candela M; Generini S; De Francisci A; Tirri E; Proietti M; Bombardieri S; Gabrielli A; Tonietti G; Cerinic MM
J Rheumatol; 2002 Apr; 29(4):731-6. PubMed ID: 11950014
[TBL] [Abstract][Full Text] [Related]
24. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis.
Clements PJ; Roth MD; Elashoff R; Tashkin DP; Goldin J; Silver RM; Sterz M; Seibold JR; Schraufnagel D; Simms RW; Bolster M; Wise RA; Steen V; Mayes MD; Connelly K; Metersky M; Furst DE;
Ann Rheum Dis; 2007 Dec; 66(12):1641-7. PubMed ID: 17485423
[TBL] [Abstract][Full Text] [Related]
25. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease.
Strange C; Bolster MB; Roth MD; Silver RM; Theodore A; Goldin J; Clements P; Chung J; Elashoff RM; Suh R; Smith EA; Furst DE; Tashkin DP;
Am J Respir Crit Care Med; 2008 Jan; 177(1):91-8. PubMed ID: 17901414
[TBL] [Abstract][Full Text] [Related]
26. Adverse events during the Scleroderma Lung Study.
Furst DE; Tseng CH; Clements PJ; Strange C; Tashkin DP; Roth MD; Khanna D; Li N; Elashoff R; Schraufnagel DE;
Am J Med; 2011 May; 124(5):459-67. PubMed ID: 21531236
[TBL] [Abstract][Full Text] [Related]
27. [Pulmonary manifestations of systemic scleroderma: pathophysiologic and clinical significance of the activation of lung fibroblasts].
Behr J; Adelmann-Grill BC; Hein R; Schwaiblmair M; Degenkolb B; Krombach F; Fruhmann G
Pneumologie; 1995 Apr; 49(4):266-72. PubMed ID: 7792285
[TBL] [Abstract][Full Text] [Related]
28. [Bronchoalveolar lavage fluid findings in rheumatoid arthritis].
Ishioka S; Inyaku K; Shirotani Y; Nakamura K; Oyama T; Hozawa S; Takahashi K; Yamakido M
Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Apr; 30(4):614-8. PubMed ID: 1405077
[TBL] [Abstract][Full Text] [Related]
29. Pulmonary involvement in diffuse cutaneous systemic sclerosis: broncheoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis.
Witt C; Borges AC; John M; Fietze I; Baumann G; Krause A
Ann Rheum Dis; 1999 Oct; 58(10):635-40. PubMed ID: 10491363
[TBL] [Abstract][Full Text] [Related]
30. Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis.
Clements PJ; Goldin JG; Kleerup EC; Furst DE; Elashoff RM; Tashkin DP; Roth MD
Arthritis Rheum; 2004 Jun; 50(6):1909-17. PubMed ID: 15188367
[TBL] [Abstract][Full Text] [Related]
31. Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre.
Beretta L; Caronni M; Raimondi M; Ponti A; Viscuso T; Origgi L; Scorza R
Clin Rheumatol; 2007 Feb; 26(2):168-72. PubMed ID: 16614793
[TBL] [Abstract][Full Text] [Related]
32. [Correlation between bronchoalveolar lavage and lung function in patients with systemic sclerosis and rheumatoid arthritis].
Pejcić T; Stanković I; Rancić M; Djordjević I; Ristić L; Vojinović J
Srp Arh Celok Lek; 2005 Dec; 133 Suppl 2():129-33. PubMed ID: 16535997
[TBL] [Abstract][Full Text] [Related]
33. [Phenotype of lymphocytes in bronchoalveolar lavage fluid of patients with lung fibrosis in the course of scleroderma].
Domagała-Kulawik J; Hoser G; Doboszyńska A; Kawiak J; Droszcz W
Pneumonol Alergol Pol; 1995; 63(7-8):382-8. PubMed ID: 8520554
[TBL] [Abstract][Full Text] [Related]
34. [Cytological examination of bronchoalveolar lavage fluid and its clinical significance in patients with diffuse interstitial lung diseases].
Li ZH; Hou XM; Li BJ
Zhonghua Nei Ke Za Zhi; 1990 Jan; 29(1):2-4, 59. PubMed ID: 2401165
[TBL] [Abstract][Full Text] [Related]
35. Induced sputum as a tool for early detection of airway inflammation in connective diseases-related lung involvement.
Vatrella A; Bocchino M; Perna F; Scarpa R; Galati D; Spina S; Pelaia G; Cazzola M; Sanduzzi A
Respir Med; 2007 Jul; 101(7):1383-9. PubMed ID: 17369033
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.
Bérezné A; Ranque B; Valeyre D; Brauner M; Allanore Y; Launay D; Le Guern V; Kahn JE; Couderc LJ; Constans J; Cohen P; Mahr A; Pagnoux C; Hachulla E; Kahan A; Cabane J; Guillevin L; Mouthon L
J Rheumatol; 2008 Jun; 35(6):1064-72. PubMed ID: 18464307
[TBL] [Abstract][Full Text] [Related]
37. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis.
Prasse A; Pechkovsky DV; Toews GB; Schäfer M; Eggeling S; Ludwig C; Germann M; Kollert F; Zissel G; Müller-Quernheim J
Arthritis Rheum; 2007 May; 56(5):1685-93. PubMed ID: 17469163
[TBL] [Abstract][Full Text] [Related]
38. Mast cells' contribution to the fibrosing alveolitis of the scleroderma lung.
Chanez P; Lacoste JY; Guillot B; Giron J; Barnéon G; Enander I; Godard P; Michel FB; Bousquet J
Am Rev Respir Dis; 1993 Jun; 147(6 Pt 1):1497-502. PubMed ID: 8503561
[TBL] [Abstract][Full Text] [Related]
39. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma.
Davas EM; Peppas C; Maragou M; Alvanou E; Hondros D; Dantis PC
Clin Rheumatol; 1999; 18(6):455-61. PubMed ID: 10638770
[TBL] [Abstract][Full Text] [Related]
40. [Clinical value of bronchoalveolar lavage in progressive systemic scleroderma (author's transl)].
König G; Luderschmidt C; Clocuh YP; Scherer U; Fruhmann G
Dtsch Med Wochenschr; 1982 May; 107(19):723-7. PubMed ID: 7075490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
